

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on 30 Nov 2000.

[Signature]
Attorney for Applicant(s)

30 Nov 2000
Date of Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) **BEN SHEN, WEN LIU, STEVEN D. CHRISTENSON, and SCOTT STANDAGE**

Assignee: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA**

Title: **GENE CLUSTER FOR PRODUCTION OF THE ENEDIYNE ANTITUMOR ANTIBIOTIC C-1027**

Serial No.: **09/478,188**

Filing Date: **January 5, 2000**

Examiner: **K. Kerr**

Art Unit: **1652**

Docket No.: **M-8960-1US**

6/a
HQ
12/18/00
RECEIVED

DEC 18 2000

TECH CENTER 1600/2900

RECEIVED

DEC 27 2000

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
Washington, D. C. 20231

AMENDMENT

Dear Sir:

In response to the Office Action dated May 31, 2000, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks. A change in correspondence address and a petition to extend the period of response for five months is enclosed. For the convenience of the Examiner, a list of the pending claims is attached as Appendix I.

In the Specification:

After the abstract, please delete the existing Sequence Listing and insert the accompanying Sequence Listing (pages 1-67) containing SEQ ID NOs: 1-102.

REMARKS

Applicants request entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. This amendment is provided to comply with the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. This amendment is accompanied by a floppy disk containing the

